文献速递造血干细胞移植与细胞治疗

供者年龄与亲缘关系对单倍体移植联合移植后环磷酰胺结局的影响

Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
PubMed 文献 · Blood Adv · 2021-01-01

该研究纳入2002至2017年接受非清髓单倍体移植联合移植后环磷酰胺的889例成人患者,中位随访2.5年。父母供者结局劣于同胞供者。

要点

  • 父母供者结局劣于同胞供者,多供者时优先选择年轻成人供者。

核心结论

  • 供者年龄增长与非清髓单倍体移植联合PTCy后更差的总生存、无进展生存及更高GVHD风险相关。
  • 父母供者结局劣于同胞供者,多供者可选时优先选择最年轻的成人供者。

研究设计与样本

  • 回顾性队列研究,纳入2002至2017年889例连续接受非清髓单倍体移植联合PTCy的成人患者。
  • 中位随访2.5年,受者中位年龄59岁(范围18-76),供者中位年龄40岁(范围13-79)。

主要发现

  • 父母供者结局劣于同胞供者,父母供者之间无显著差异。

临床怎么用

  • 在有多名单倍体供者可选时,优先选择最年轻的成人供者。
  • 选择供者时应考虑供者年龄和亲缘关系对移植结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic blood or marrow transplantation (BMT) physicians seek to optimize all possible variables to improve outcomes. Selectable factors include conditioning, graft-versus-host disease (GVHD) prophylaxis, graft source, and donor. Many patients, especially those with eligible haploidentical (haplo) donors, will have multiple donor options. We seek to identify factors to optimize the choice of haplo donors when using posttransplantation cyclophosphamide (PTCy) GVHD prophylaxis. We evaluated the effect of modifiable donor characteristics (donor age and relationship) on outcomes following haplo BMT with a uniform nonmyeloablative conditioning and PTCy. From 2002 to 2017, 889 consecutive adult patients underwent nonmyeloablative haplo BMT with PTCy. Median follow-up among survivors was 2.5 years after BMT. Median recipient age was 59 (range: 18 to 76) years and median donor age was 40 (range: 13 to 79) years. Multivariable analyses demonstrated that increasing donor age by decade was associated with poorer overall survival (hazard ratio [HR], 1.13 [1.05, 1.22; P = .0015]), worse progression-free survival (HR, 1.09 [1.02, 1.16; P = .015]), and a higher risk for grade 2 to 4 and grade 3 to 4 GVHD (1.3 [1.06, 1.61; P = .013]), but not for chronic GVHD (HR, 1.06 [0.94, 1.2]; P = .37). These less-favorable results with older donors were attributable to worse nonrelapse mortality (HR, 1.19 [1.05, 1.34]; P = .006), not relapse. Parents were associated with inferior outcomes compared with sibling donors, whereas no significant differences were observed between parental donors. These data suggest that the youngest, adult-sized donors should be preferred when multiple haplo donors are available.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeZern AE, Franklin C, Tsai HL, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021. PMID: 33661299. doi:10.1182/bloodadvances.2020003922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。